Related references
Note: Only part of the references are listed.Clinicopathologic features and prognostic significance of CD30 expression in de novo diffuse large B-cell lymphoma (DLBCL): results in a homogeneous series from a single institution
Maria Queralt Salas et al.
BIOMARKERS (2020)
Expression and function of FRA1 protein in tumors
Xiaoyan Jiang et al.
MOLECULAR BIOLOGY REPORTS (2020)
CDD/SPARCLE: the conserved domain database in 2020
Shennan Lu et al.
NUCLEIC ACIDS RESEARCH (2020)
Pathology and genetics of anaplastic large cell lymphoma
Vasiliki Leventaki et al.
SEMINARS IN DIAGNOSTIC PATHOLOGY (2020)
Inhibitory checkpoints in human natural killer cells: IUPHAR Review 28
F. R. Mariotti et al.
BRITISH JOURNAL OF PHARMACOLOGY (2020)
PD-1/PD-L1 Pathway and Its Blockade in Patients with Classic Hodgkin Lymphoma and Non-Hodgkin Large-Cell Lymphomas
Wei Xie et al.
CURRENT HEMATOLOGIC MALIGNANCY REPORTS (2020)
Selective antagonism of cJun for cancer therapy
Andrew Brennan et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2020)
From bench to bedside: the past, present and future of therapy for systemic paediatric ALCL, ALK
Hugo Larose et al.
BRITISH JOURNAL OF HAEMATOLOGY (2019)
Inflammatory regulatory network mediated by the joint action of NF-kB, STAT3, and AP-1 factors is involved in many human cancers
Zhe Ji et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)
A novel model of controlling PD-L1 expression in ALK+ anaplastic large cell lymphoma revealed by CRISPR screening
Jing-Ping Zhang et al.
BLOOD (2019)
AP-1 Transcription Factors as Regulators of Immune Responses in Cancer
Vasileios Atsaves et al.
CANCERS (2019)
CD30-positive primary cutaneous lymphoproliferative disorders: molecular alterations and targeted therapies
Lucia Prieto-Torres et al.
HAEMATOLOGICA (2019)
Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial
Steven Horwitz et al.
LANCET (2019)
An oncogenic axis of STAT-mediated BATF3 upregulation causing MYC activity in classical Hodgkin lymphoma and anaplastic large cell lymphoma
A. Lollies et al.
LEUKEMIA (2018)
S1PR1 drives a feedforward signalling loop to regulate BATF3 and the transcriptional programme of Hodgkin lymphoma cells
K. Vrzalikova et al.
LEUKEMIA (2018)
Efficacy of nivolumab in a patientwith systemic refractory ALK plus anaplastic large cell lymphoma
Charlotte Rigaud et al.
PEDIATRIC BLOOD & CANCER (2018)
Hodgkin lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
D. A. Eichenauer et al.
ANNALS OF ONCOLOGY (2018)
Lymphotoxin in physiology of lymphoid tissues - Implication for antiviral defense
Ekaterina P. Koroleva et al.
CYTOKINE (2018)
The role of lymphotoxin-α in rheumatoid arthritis
Tomohiro Hirose et al.
INFLAMMATION RESEARCH (2018)
The AP-1-BATF and-BATF3 module is essential for growth, survival and TH17/ILC3 skewing of anaplastic large cell lymphoma
Nikolai Schleussner et al.
LEUKEMIA (2018)
Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma
J. M. Connors et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Role of activating transcription factor 3 and its interacting proteins under physiological and pathological conditions
M. Rohini et al.
INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES (2018)
Challenges of driving CD30-directed CAR-T cells to the clinic
Natalie S. Grover et al.
BMC CANCER (2018)
The c-Jun and JunB transcription factors facilitate the transit of classical Hodgkin lymphoma tumour cells through G(1)
Jingxi Zhang et al.
SCIENTIFIC REPORTS (2018)
The AP-1 transcription factor JunB is essential for multiple myeloma cell proliferation and drug resistance in the bone marrow microenvironment
F. Fan et al.
LEUKEMIA (2017)
Inactivation of the putative ubiquitin-E3 ligase PDLIM2 in classical Hodgkin and anaplastic large cell lymphoma
K. D. Wurster et al.
LEUKEMIA (2017)
Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma
Robert Chen et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Understanding CD30 biology and therapeutic targeting: a historical perspective providing insight into future directions
C. A. van der Weyden et al.
BLOOD CANCER JOURNAL (2017)
AP-1 Expression and its Clinical Relevance in Immune Disorders and Cancer
Shivtia Trop-Steinberg et al.
AMERICAN JOURNAL OF THE MEDICAL SCIENCES (2017)
Nivolumab for Refractory Anaplastic Large Cell Lymphoma: A Case Report
Holger Hebart et al.
ANNALS OF INTERNAL MEDICINE (2016)
Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma
Robert Chen et al.
BLOOD (2016)
Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure
Philippe Armand et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
A positive feedback loop involving the Wnt/β-catenin/MYC/Sox2 axis defines a highly tumorigenic cell subpopulation in ALK-positive anaplastic large cell lymphoma
Chengsheng Wu et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2016)
Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial
Anas Younes et al.
LANCET ONCOLOGY (2016)
PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations
Weiping Zou et al.
SCIENCE TRANSLATIONAL MEDICINE (2016)
Hodgkin lymphoma: Pathology and biology
Stephan Mathas et al.
SEMINARS IN HEMATOLOGY (2016)
Constitutive control of AKT1 gene expression by JUNB/CJUN in ALK plus anaplastic large-cell lymphoma: a novel crosstalk mechanism
V. Atsaves et al.
LEUKEMIA (2015)
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
Stephen M. Ansell et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Essential role of IRF4 and MYC signaling for survival of anaplastic large cell lymphoma
Andre Weilemann et al.
BLOOD (2015)
Jun-regulated genes promote interaction of diffuse large B-cell lymphoma with the microenvironment
Marzenna Blonska et al.
BLOOD (2015)
c-Fos: An AP-1 transcription factor with an additional cytoplasmic, non-genomic lipid synthesis activation capacity
Beatriz L. Caputto et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS (2014)
Reed-Sternberg cell-derived lymphotoxin-α activates endothelial cells to enhance T-cell recruitment in classical Hodgkin lymphoma
Chee Wai Fhu et al.
BLOOD (2014)
The oncogenic JUNB/CD30 axis contributes to cell cycle deregulation in ALK plus anaplastic large cell lymphoma
Vassilis Atsaves et al.
BRITISH JOURNAL OF HAEMATOLOGY (2014)
AP-1/c-Jun transcription factors: Regulation and function in malignant melanoma
Melanie Kappelmann et al.
EUROPEAN JOURNAL OF CELL BIOLOGY (2014)
c-JUN N-terminal kinase (JNK) is activated and contributes to tumor cell proliferation in classical Hodgkin lymphoma
Vasiliki Leventaki et al.
HUMAN PATHOLOGY (2014)
Small Molecule Inhibitors Targeting Activator Protein 1 (AP-1)
Na Ye et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
Expression of granzyme B sensitizes ALK plus ALCL tumour cells to apoptosis-inducing drugs
Joel D. Pearson et al.
MOLECULAR CANCER (2014)
A novel tetravalent bispecific TandAb (CD30/CD16A) efficiently recruits NK cells for the lysis of CD30+ tumor cells
Uwe Reusch et al.
MABS (2014)
Mapping of transcription factor motifs in active chromatin identifies IRF5 as key regulator in classical Hodgkin lymphoma
Stephan Kreher et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
The microenvironment in classical Hodgkin lymphoma: An actively shaped and essential tumor component
Yuxuan Liu et al.
SEMINARS IN CANCER BIOLOGY (2014)
GSK3-SCFFBXW7 targets JunB for degradation in G2 to preserve chromatid cohesion before anaphase
B. Perez-Benavente et al.
ONCOGENE (2013)
Ets-1 Activates Overexpression of JunB and CD30 in Hodgkin's Lymphoma and Anaplastic Large-Cell Lymphoma
Mariko Watanabe et al.
AMERICAN JOURNAL OF PATHOLOGY (2012)
The heat shock protein-90 co-chaperone, Cyclophilin 40, promotes ALK-positive, anaplastic large cell lymphoma viability and its expression is regulated by the NPM-ALK oncoprotein
Joel D. Pearson et al.
BMC CANCER (2012)
Constitutive AP-1 Activity and EBV Infection Induce PD-L1 in Hodgkin Lymphomas and Posttransplant Lymphoproliferative Disorders: Implications for Targeted Therapy
Michael R. Green et al.
CLINICAL CANCER RESEARCH (2012)
Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma: Results of a Phase II Study
Barbara Pro et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
PDGFR blockade is a rational and effective therapy for NPM-ALK-driven lymphomas
Daniela Laimer et al.
NATURE MEDICINE (2012)
Controlling Cytoplasmic c-Fos Controls Tumor Growth in the Peripheral and Central Nervous System
German A. Gil et al.
NEUROCHEMICAL RESEARCH (2012)
NPM-ALK signals through glycogen synthase kinase 3β to promote oncogenesis
S. R. P. McDonnell et al.
ONCOGENE (2012)
Targeting inflammation by modulating the Jun/AP-1 pathway
Helia B. Schonthaler et al.
ANNALS OF THE RHEUMATIC DISEASES (2011)
Activation and function of immediate-early genes in the nervous system
Beatriz Perez-Cadahia et al.
BIOCHEMISTRY AND CELL BIOLOGY (2011)
Hallmarks of Cancer: The Next Generation
Douglas Hanahan et al.
CELL (2011)
Targeted Repression of Overexpressed CD30 Downregulates NF-κB and ERK1/2 Pathway in Hodgkin Lymphoma Cell Lines
Mariko Watanabe et al.
ONCOLOGY RESEARCH (2011)
Jun Proteins Are Starvation-Regulated Inhibitors of Autophagy
Orli Yogev et al.
CANCER RESEARCH (2010)
AP-1 (Fra-1/c-Jun)-mediated Induction of Expression of Matrix Metalloproteinase-2 Is Required for 15(S)-Hydroxyeicosatetraenoic Acid-induced Angiogenesis
Nikhlesh K. Singh et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas.
Anas Younes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Sonic Hedgehog Signaling Pathway Is Activated in ALK-Positive Anaplastic Large Cell Lymphoma
Rajesh R. Singh et al.
CANCER RESEARCH (2009)
Pathogenesis of rheumatoid arthritis and c-Fos/AP-1
Shunichi Shiozawa et al.
CELL CYCLE (2009)
Cutting Edge: The PTPN22 Allelic Variant Associated with Autoimmunity Impairs B Cell Signaling
Adrian F. Arechiga et al.
JOURNAL OF IMMUNOLOGY (2009)
Intracellular versus extracellular granzyme B in immunity and disease: challenging the dogma
Wendy Anne Boivin et al.
LABORATORY INVESTIGATION (2009)
Transcription Factors in Long-Term Memory and Synaptic Plasticity
Cristina M. Alberini
PHYSIOLOGICAL REVIEWS (2009)
Transcriptional Control of Skeletogenesis
Gerard Karsenty
Annual Review of Genomics and Human Genetics (2008)
Adult life after surviving lymphoma in childhood
Nicolas X. von der Weid
SUPPORTIVE CARE IN CANCER (2008)
Hypomethylation of CD30 CpG islands with aberrant JunB expression drives CD30 induction in Hodgkin lymphoma and anaplastic large cell lymphoma
Mariko Watanabe et al.
LABORATORY INVESTIGATION (2008)
The oncoprotein NPM-ALK of anaplastic large-cell lymphoma induces JUNB transcription via ERK1/2 and JunB translation via mTOR signaling
Philipp B. Staber et al.
BLOOD (2007)
NPM-ALK oncogenic kinase promotes cell-cycle progression through activation of JNK/cJun signaling in anaplastic large-cell lymphoma
Vasiliki Leventaki et al.
BLOOD (2007)
Galectin-1 mediated suppression of Epstein-Barr virus-specific T-cell immunity in classic Hodgkin lymphoma
Maher K. Gandhi et al.
BLOOD (2007)
The AP1-dependent secretion of galectin-1 by Reed - Sternberg cells fosters immune privilege in classical Hodgkin lymphoma
Przemyslaw Juszczynski et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
JunB is a gatekeeper for B-lymphoid leukemia
R. G. Ott et al.
ONCOGENE (2007)
The activator protein-1 transcription factor in respiratory epithelium carcinogenesis
Michalis V. Karamouzis et al.
MOLECULAR CANCER RESEARCH (2007)
The molecular understanding of osteoclast differentiation
Masataka Asagiri et al.
BONE (2007)
Transcription factors control invasion: AP-1 the first among equals
B. W. Ozanne et al.
ONCOGENE (2007)
c-Jun expression and activation are restricted to CD30(+) lymphoproliferative disorders
Elias Drakos et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2007)
The expression of CD30 in anaplastic large cell lymphoma is regulated by nucleophosmin-anaplastic lymphoma kinase-mediated JunB level in a cell type-specific manner
Faye Yuan-Yi Hsu et al.
CANCER RESEARCH (2006)
Activation of mammalian target of rapamycin signaling pathway contributes to tumor cell survival in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma
Francisco Vega et al.
CANCER RESEARCH (2006)
Role of the AP-1 transcription factor c-Jun in developing, adult and injured brain
Gennadij Raivich et al.
PROGRESS IN NEUROBIOLOGY (2006)
Constitutive activation of STAT proteins in the HDLM-2 and L540 Hodgkin lymphoma-derived cell lines supports cell survival
O Cochet et al.
CELLULAR SIGNALLING (2006)
Classical Hodgkin lymphoma is characterized by high constitutive expression of activating transcription factor 3 (ATF3), which promotes viability of Hodgkin/Reed-Sternberg cells
M Janz et al.
BLOOD (2006)
Fos/AP-1 proteins in bone and the immune system
EF Wagner et al.
IMMUNOLOGICAL REVIEWS (2005)
JunB expression is a common feature of CD30+lymphomas and lymphomatoid papulosis
GZ Rassidakis et al.
MODERN PATHOLOGY (2005)
JunB induced by constitutive CD30-extracellular signal-regulated kinase 1/2 mitogen-activated protein kinase signaling activates the CD30 promoter in anaplastic large cell lymphoma and Reed-Sternberg cells of Hodgkin lymphoma
M Watanabe et al.
CANCER RESEARCH (2005)
Constitutive activation of phosphatidyl-inositide 3 kinase contributes to the survival of Hodgkin's lymphoma cells through a mechanism involving Akt kinase and mTOR
A Dutton et al.
JOURNAL OF PATHOLOGY (2005)
Inhibition of Akt increases P27KiP1 levels and induces cell cycle arrest in anaplastic large cell lymphoma
GZ Rassidakis et al.
BLOOD (2005)
Jak3 activation is significantly associated with ALK expression in anaplastic large cell lymphoma
R Lai et al.
HUMAN PATHOLOGY (2005)
Differential signaling pathways are activated in the Epstein-Barr virus-associated malignancies nasopharyngeal carcinoma and Hodgkin lymphoma
JA Morrison et al.
CANCER RESEARCH (2004)
NPM-ALK fusion kinase of anaplastic large-cell lymphoma regulates survival and proliferative signaling through modulation of FOXO3a
TL Gu et al.
BLOOD (2004)
Structure/function analysis of the murine CD95L promoter reveals the identification of a novel transcriptional repressor and functional CD28 response element
SA Crist et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Inhibition of JAK3 induces apoptosis and decreases anaplastic lymphoma kinase activity in anaplastic large cell lymphoma
HM Amin et al.
ONCOGENE (2003)
AP-1 mediated relief of repressive activity of the CD30 promoter microsatellite in Hodgkin and Reed-Sternberg cells
M Watanabe et al.
AMERICAN JOURNAL OF PATHOLOGY (2003)
A role for AP-1 in apoptosis: the case for and against
M Ameyar et al.
BIOCHIMIE (2003)
Development of potent monoclonal antibody auristatin conjugates for cancer therapy
SO Doronina et al.
NATURE BIOTECHNOLOGY (2003)
Amplification and overexpression of JUNB is associated with primary cutaneous T-cell lymphomas
X Mao et al.
BLOOD (2003)
JunB inhibits proliferation and transformation in B-lymphoid cells
AP Szremska et al.
BLOOD (2003)
Role and regulation of activator protein-1 in toxicant-induced responses of the lung
SPM Reddy et al.
AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY (2002)
Aberrantly expressed c-Jun and JunB are a hallmark of Hodgkin lymphoma cells, stimulate proliferation and synergize with NF-κB
S Mathas et al.
EMBO JOURNAL (2002)
Promoter specificity and biological activity of tethered AP-1 dimers
L Bakiri et al.
MOLECULAR AND CELLULAR BIOLOGY (2002)
AP-1 as a regulator of cell life and death
E Shaulian et al.
NATURE CELL BIOLOGY (2002)
Anaplastic lymphoma kinase (ALK) activates Stat3 and protects hematopoietic cells from cell death
A Zamo et al.
ONCOGENE (2002)
Signal transducer and activator of transcription 6 is frequently activated in Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma
BF Skinnider et al.
BLOOD (2002)
Multilevel dysregulation of STAT3 activation in anaplastic lymphoma kinase-positive T/null-cell lymphoma
Q Zhang et al.
JOURNAL OF IMMUNOLOGY (2002)
STAT3 is constitutively activated in Hodgkin cell lines
D Kube et al.
BLOOD (2001)
Close encounters of many kinds: Fos-Jun interactions that mediate transcription regulatory specificity
Y Chinenov et al.
ONCOGENE (2001)
AP-1 proteins in the adult brain: facts and fiction about effectors of neuroprotection and neurodegeneration
T Herdegen et al.
ONCOGENE (2001)
AP-1 in mouse development and tumorigenesis
W Jochum et al.
ONCOGENE (2001)
AP-1 in cell proliferation and survival
E Shaulian et al.
ONCOGENE (2001)
Nucleophosmin-anaplastic lymphoma kinase associated with anaplastic large-cell lymphoma activates the phosphatidylinositol 3-kinase/Akt antiapoptotic signaling pathway
RY Bai et al.
BLOOD (2000)
Share Paper
